The Protective Effects of Ciji-Hua’ai-Baosheng II Formula on Chemotherapy-Treated H₂₂ Hepatocellular Carcinoma Mouse Model by Promoting Tumor Apoptosis

Biqian Fu†1, Shengyan Xi1,2,3,*, Yanhui Wang1,2,3, Xiangyang Zhai1, Yanan Wang1, Yuwen Gong4, Yangxinzi Xu5, Jiaqi Yang5, Yingkun Qiu6, Jing Wang6, Dawei Lu1 and Shuqiong Huang1

†These authors have contributed equally to this work as co-first authors

1 Department of Traditional Chinese Medicine, Medical College, Xiamen University, Xiamen, China, 2 Cancer Research Center, Xiamen University, Xiamen, China, 3 Department of Traditional Chinese Medicine, Xiang’an Hospital of Xiamen University, Xiamen, China, 4 College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada, 5 Department of Physiology, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada, 6 School of Pharmaceutical Sciences, Xiamen University, Xiamen, China

Ciji-Hua’ai-Baosheng II Formula (CHB-II-F) is a traditional Chinese medical formula that has been shown in clinical practice to relieve side effects of chemotherapy and improve quality of life for cancer patients. In order to understand the mechanism of its protective effects on chemotherapy, mice with transplanted H₂₂ hepatocellular carcinoma were employed in this study. Ninety-two mice were injected subcutaneously with H₂₂ HCC cell suspension into the right anterior armpit. After mice were treated with 5-fluorouracil (5-FU), they were divided into six groups as untreated group, 5-FU group, 5-FU plus Yangzheng Xiaoji Capsule group and three groups of 5-FU plus different concentrations of CHB-II-F. Twenty mice were euthanized after 7 days of treatment in untreated and medium concentration of CHB-II-F groups and all other mice were euthanized after 14 days of treatment. Herbal components/metabolites were analyzed by UPLC-MS. Tumors were evaluated by weight and volume, morphology of light and electron microscope, and cell cycle. Apoptosis were examined by apoptotic proteins expression by western blot. Four major components/metabolites were identified from serum of mice treated with CHB-II-F and they are β-Sitosterol, Salvianolic acid, isobavachalcone, and bakuchiol. Treatment of CHB-II-F significantly increased body weights of mice and decreased tumor volume compared to untreated group. Moreover, CHB-II-F treatment increased tumor cells in G₀-G₁ transition instead of in S phase. Furthermore, CHB-II-F treatment increased the expression of pro-apoptotic proteins and decreased the expression anti-apoptotic protein. Therefore, CHB-II-F could improve mice general condition and reduce tumor cell malignancy. Moreover, CHB-II-F regulates apoptosis of tumor cells, which could contribute its protective effect on chemotherapy.

Keywords: Ciji-Hua’ai-Baosheng II Formula, chemotherapy, H₂₂ hepatocellular carcinoma, Bcl-2, Bax, caspase-3, caspase-8, caspase-9
INTRODUCTION

Hepatocellular carcinoma is one of the most common cancers in the world and the third leading cause of cancer death. Moreover, it remains one of the most common malignant tumors in China. Surgery, radiotherapy and chemotherapy are among the common treatment options for patients with hepatocellular carcinoma. However, cancer recurrence, metastasis and side-effects of chemotherapy are the major concerns regarding to the prognosis of patients (Balistreri et al., 2005; Ciarimboli, 2012; Kudo et al., 2014; Tedore, 2015). Especially, side effects of chemotherapy such as fatigue, bone marrow suppression and gastrointestinal aversions lead to a dramatic decrease in quality of life (Ciarimboli, 2012; Xi et al., 2016; Ma et al., 2018). In recent years, traditional Chinese herbal medicine has been employed after chemotherapy to relieve adverse reactions and improve patient tolerance to chemotherapy (Liu, 2012). For instance, Shenling Baizhu powder is used to treat patients with leukemia receiving chemotherapy (Liu et al., 2012); Gujin Moji tablet has been shown to protect and promote bone marrow hematopoesis in tumor-bearing mice with chemotherapy (Chen et al., 1998). Early studies revealed that first generation Ciji-Hua'ai-Baosheng Formula can prolong life of mice with transplanted ascitic H22 hepatocellular carcinoma, inhibit tumor growth, antagonize the decrease of white blood cells and platelets following chemotherapy, promote the production and activity of erythropoietin (EPO) and granulocyte-macrophage colony stimulating factor (GM-CSF), maintain the stability of peripheral blood cells, and improve immune functions (Xi et al., 2014; Cheng et al., 2016; Xi et al., 2018).

Professor Wang Yanhui, a prominent TCM practitioner, has used TCM to treat patients with malignant tumors. He believed that pathological changes in the internal environment of the body, such as productions of phlegm, dampness, and blood stasis initiate the occurrence of tumor. Clinically, malignant tumors are treated with surgery and/or a combination of radiotherapy and chemotherapy. Although tumor is targeted and removed, metastasis (Lai et al., 2014). CHB-II-F is formulated based on Professor Wang's extensive clinical experience (Wang and Xi, 2017), and is a second generation of formula refined from the original Ciji Hua'ai Baosheng Decoction (CHBD) (Cheng et al., 2016; Xi et al., 2018) without changing the principles of treatment in order to better facilitate its subsequent applications and further development. CHB-II-F is consisted of Radix Codonopsis, Semen Ziziphi Spinosae, Fructus Hordei Germinatus, Pericarpium Citri Reticulatae, Poria, Concha Ostreae, Bulbus Fritillariae Ussuriensis and Radix Salviae Miltiorrhizae. This formula is organized to help removing the pathological products while supplementing the body. Its aim is to restore balance to the internal environment, reduce tumor recurrence and metastasis, and improve the patient's quality of life (Wang, 2004; Wang and Shen, 2004; Lai et al., 2014; Li et al., 2017; Liu et al., 2017).

5-fluorine pyrimidine, the most widely used pyrimidine drugs, has good curative effect on digestive tract cancers such as colon cancer, rectal cancer, gastric cancer, liver cancer, and other solid tumors, but has lots of side-effects that include hepatotoxicity and nephrotoxicity (Chinese Pharmacopoeia Commission [CPC], 2015b; Gelen et al., 2018). In China, Chinese physicians usually select 5-FU to combine with TCMs in order to reduce its bone marrow suppression, hepatorenal toxicity and gastrointestinal adverse reactions (Liu and Xie, 2018; Wang et al., 2018). YZXJC, a Chinese patent medicine approved by the State Drug Administration (SDA) of China for the treatment of primary hepatocellular carcinoma, is recorded in the Pharmacopoeia of the People's Republic of China (Chinese Pharmacopoeia Commission [CPC], 2015a), and it has been widely used in clinical practice in China and its efficacy has been clinically confirmed. Therefore, 5-FU and YZXJC were used as chemotherapeutic drug and herbal treatment drug in this study, respectively.

Apoptosis is a process of cell deaths featuring DNA fragmentation. Malignant tumor is related to not only increased cell proliferation, but also inhibition of cell apoptosis (Xi et al., 2016). Apoptosis is a complex cellular process regulated by many factors, such as Bcl-2 and Bax (Pan et al., 2014). From the current point of view, apoptosis is mainly regulated by two pathways: the pressure-induced pathway and the death receptor mediated pathway (Wang et al., 2011). The latter process depends on activation of death receptor, which triggers activation of caspases through formation of a death signal complex and promote apoptosis of tumor cells (Mcllwain et al., 2015).

Ciji-Hua'ai-Baosheng II Formula exhibits significant clinical benefits for patients after radiotherapy and chemotherapy. It is speculated that CHB-II-F may have anti-tumor effects, but molecular mechanism for its anti-tumor activity is not clear at present. The aim of this study is to investigate beneficial effects of the CHB-II-F formula on chemotherapy-treated mice, possible effects on apoptosis of tumor cells, and its possible anti-tumor mechanism.

MATERIALS AND METHODS

Experimental Animals and Tumor Cells

Forty-six male and forty-six female special pathogen-free (SPF) Kunming mice, 18–22 g and aged 4–6 weeks, were purchased from Laboratory Animal Centre of Xiamen University in Xiamen, China (License No. SCXX (Min) 2017-005). The animals were given 1 week to adapt to the new environment before experimentation. All experimental procedures were approved by the Laboratory Animal Administration and Ethics Committee of Xiamen University (No. XMULAC 2012-0039). The H22 hepatoma cell suspension was provided by the Cancer Research Centre of Xiamen University (Xiamen, China).

Experimental Drugs

Ciji-Hua'ai-Baosheng II Formula is composed of Radix Codonopsis, Semen Ziziphi Spinosae, Fructus Hordei

Abbreviations: 5-FU, 5-fluorine pyrimidine; CHB-II-F, Ciji-Hua'ai-Baosheng II Formula; H&E, hematoxylin and eosin; HCC, hepatocellular carcinoma cells; TCM, traditional Chinese medicine; UHPLC, ultra-high performance liquid chromatography; YZXJC, Yangzheng Xiaoji capsule.
Germinatus, Pericarpium Citri Reticulatae, Poria, Concha Ostreae, Bulbus Fritillariae Ussurienisis and Radix Salviae Miltiorrhizae (See Table 1) It was purchased from the Yanlaifu Pharmaceutical Co., Ltd. (Xiamen, China). Its chemical fingerprint (UHPLC) of CHB-II-F has been analyzed (See Figure 1) and the detailed methods of UHPLC is provided in the Supplementary Data. 5-fluorouracil, 5-FU (#1607261) was purchased from Tianjin Jinyao Pharmaceutical Co., Ltd. (Tianjin, China). 0.9% Sodium Chloride (#1702232) contained 100 mL in each ampoule. This product was produced by Fujian Tianquan Pharmaceutical Co., Ltd. (Longyan, China). YZXJC, with a product lot number of A1509006, was contained 0.39 g in each capsule. This product was produced by Shijiazhuang Yiling Pharmaceutical Co., Ltd. (Shijiazhuang, China).

Main Reagents
In this study, we used the following materials: Annexin V-FITC/PI Apoptosis Detection Kit (product lot No. FXP018-100) and Cell Cycle Analysis Kit (product No. FXP021-100) were purchased from Beijing 4A Biotech Co., Ltd. (Beijing, China). Caspase-3 Antibody (product No. AB030), active caspase-3 antibody (product No. AC033), active caspase-8 antibody (product No. AC056), active caspase-9 antibody (product No. AC062), Bcl-2 antibody (product No. AB112), and Bax antibody (product No. AB026) were purchased from Beijing 4A Biotech Co., Ltd. (Beijing, China).

Establishment of Chemotherapy-Treated H22 Hepatocellular Carcinoma Mouse Model
Hepatoma cells from Kunming mice with primary ascitic hepatoma cell H22 were collected under sterile condition and counted with a cell counter. Cells were then diluted with saline to a concentration of 2 × 10⁷ cells/mL and injected into SPF Kunming mice at a volume of 0.2 mL/10 g body weight subcutaneously at the right armpit. Seven days after injection, 92 mice have successfully developed tumors at the injected site.

| Chinese name | Botanical name | Common name | Weight (g) | Voucher numbers | Part used |
|--------------|---------------|-------------|------------|----------------|----------|
| Dang Shen    | Codonopsis pilosula (Franch.) Nannf., Codonopsis pilosula Nannf.var. modesta (Nannf.) L.T. Shen or Codonopsis tangshen Oliv. | Radix Codonopsis | 10         | 160201    | Root and rhizome |
| Fu Ling      | Poria cocos (Schw.) Wulf | Poria | 30         | 140130    | Sclerotium       |
| Mai Ya       | Hordeum vulgare L. | Fructus Hordei Germinatus | 20         | 131129    | Germinated matured fruit |
| Chen Pi      | Citrus reticulata Blanco | Pericarpium Citri Reticulatae | 10        | 140123    | Matured pericarp |
| Ping Bei Mu  | Fritillaria ussuriensis Maxim | Bulbus Fritillariae ussuriensis | 30        | 140130    | Squamous bulb |
| Mu Li        | Ostrea gigas Thunberg, Ostrea talenwhanensis Crosse or Ostrea rivulaires Gould | Concha Ostreae | 20        | 160201    | Shell |
| Dan Shen     | Salvia miltiorrhiza Bge | Radix Salviae Miltiorrhizae | 50        | 161013    | Root and rhizome |
| Suan Zao Ren | Ziziphus jujuba Mill. var. spinosa (Bunge) Hu ex H. F. Chou | Semen Ziziphi Spinosae | 25        | 140130    | Matured seed |
FIGURE 1 | (A) UHPLC-MS chemical fingerprint of CHB-II-F. (B) Chemical structure of the major identified components of CHB-II-F, 3,4-Dihydroxybenzaldehyde (1), Caffeic acid (2), Spinosin (3), Baicalin (4), Salvianolic acid C (5), Hesperidin (6), Rosmarinic acid (7), Salvianolic acid B (8), Lithospermic acid (9), and Nobiletin (10).
site. These mice then received peritoneal injections of 5-FU at 200 mg/kg to establish the chemotherapy-treated HCC model.

**Animal Groupings, Modeling and Drug Administration**

Ninety-two chemotherapy-treated mice with H22 HCC were randomly divided into 6 study groups: physiologic saline (negative control), 5-FU (20 mg/kg), the YZXJC (0.78 g/kg) treatment, and three CHB-II-F [CHB-II-F (L), CHB-II-F (M), CHB-II-F (H), respectively] treatments. CHB-II-F groups received drug concentration of 0.8125, 1.625, and 3.25 g/mL [CHB-II-F (L), CHB-II-F (M), or CHB-II-F (H), respectively] by intragastric administration once a day for 14 days. The 5-FU group received peritoneal injection of 5-FU at 20 mg/kg (Li et al., 2003) at a volume of 0.2 mL/10 g once every other day for 14 days. The YZXJC group received intragastric injection at 0.039 g/mL once per day for 14 days. Each group had 12 mice. Another 20 mice were added to the physiologic saline group and CHB-II-F (M) group for component/metabolite analysis at mid-way of treatment.

**UHPLC-MS**

On the 7th day of treatment, 10 mice from the saline and CHB-II-F (M) groups respectively were euthanized and peripheral blood was collected through retro-orbital bleeding. Serum was collected through centrifugation at 3000 rpm for 15 min and stored in −80℃ until further analysis. Serum was washed with methanol at 1:4 ratio, mixed on shaker for 3 min and centrifuged for 15 min at 13000 rpm. The procedure continued until no pellet was observed after centrifugation, and the supernatant was then concentrated with blowing nitrogen. Blank serum of equal volume undergoing the same procedure was used as a control.

Serum from the CHB-II-F treated group were profiled by UHPLC coupled with a high-resolution electrospray ionization mass (HR-ESI-MS) detector. Prior to the MS detector, the UHPLC separation was performed over a Cosmosil CN column (2.6 μm, 250 mm × 4.6 mm i.d., 5 μm) on a Thermo UltiMate 3000 LC system. The mobile phase was acetonitrile (A) and water with 0.1% formic acid (v/v) (B), and the constituents were eluted by gradient according to the elution program as follows: A from 5 to 35% and B from 95 to 65% during 0–30 min, A from 35 to 100% and B from 65 to 0% during 30–35 min; A and B were kept at 100 and 0% repetitively during 35–45 min. The column was maintained at 35℃ and eluted at a flow rate of 1 mL/min. The injection volume was 5 μL. A diode array detector (DAD) with detection wavelength of 254 nm and a high resolution ESI-MS detector were used to record the UHPLC chromatograms.

The MS spectra were recorded on a Thermo Q-Exactive system. The mass spectrometer of positive and negative ionizations was calibrated across m/z 100–1500 using the manufacturer's calibration standards mixture (caffeine, MRFA and Ultramark 1621 in an acetonitrile-methanol-water solution containing 1% acetic acid) allowing for mass accuracies of no more than 5ppm in the external calibration mode. The ionization voltage was 3.5 kV, and the capillary temperature was set at 300℃.

**Measurements of Tumor Volume, Weight, Inhibitory Ratio and Histology**

The tumor length (mm) (a) and tumor width (mm) (b) were measured and recorded by a sliding calipers on the 7 and 14th day after treatment in H22 HCC mice. Tumor volumes were then calculated according to the formula: V (mm3) = 1/2 × a × b2. Mice were subsequently anesthetized by ethyl ether inhalation and sacrificed by cervical dislocation. Tumors were removed and weighed. The tumor inhibitory ratio (IR) was calculated as the average tumor weight of the untreated controls minus the average tumor weight of the treatment group/average tumor weight of untreated controls × 100%. A portion of the tumor tissue was fixed in a 10% neutralized formaldehyde solution for histological analysis. Paraffin sections with a thickness of 8 μm were developed and stained with H&E. Histologic changes were observed by light microscopy (100×) and recorded by photograph.

A portion of the tumor tissue (3–5 mm3) was fixed with 2.5% glutaraldehyde stationary solution and then 1% osmic acid for 2 h. After fixation, the tumor tissue was dehydrated with acetone gradiently, made into ultrathin sections, stained with uranium acetate and lead citrate, and observed by transmission electron microscope (6000×).

**Measurement of Tumor Cell Cycle by Flow Cytometer**

Tumor tissue with a size of about 3 mm × 3 mm × 3 mm was resected, shredded, and then homogenized once on ice by Jiangyin-Jingying 5 ML glass grinders with cross-shaped handle (Jingying Glassware Co., Ltd., Jiangyin, China) with moderate force and speed for 3 s by hand. HBSS solution was added to the homogenate, filtered through a 400-mesh cell sieve, and the resultant cell suspension was collected. The cell suspension was washed with 1 mL of 75% anhydrous ethanol drop by drop, and the cell was washed twice with 400 μL of RNase A solution and then incubated in the dark at room temperature for 10 min. Then, analysis of annexin V-FITC binding and PI dyeing of cells with PI binding buffer. Annexin V-FITC (5 μL) and PI (5 μL) were added and incubated in the dark at room temperature for 10 min. Then, analysis of annexin V-FITC binding and PI staining were performed with a flow cytometer at excitation length of 488 nm.

**Measurement of Tumor Cell Apoptosis by Annexin-V FITC/PI**

A total of 1–5 × 105 tumor cells were resuspended in 100 μL of 1× binding buffer. Annexin V-FITC (5 μL) and PI (5 μL) were added and incubated in the dark at room temperature for 10 min. Then, analysis of annexin V-FITC binding and PI staining were performed with a flow cytometer at excitation length of 488 nm.

**Measurement of Tumor Cell Apoptosis by Annexin-V FITC/PI**

A total of 1–5 × 105 tumor cells were resuspended in 100 μL of 1× binding buffer. Annexin V-FITC (5 μL) and PI (5 μL) were added and incubated in the dark at room temperature for 10 min. Then, analysis of annexin V-FITC binding and PI staining were performed with a flow cytometer at excitation length of 488 nm.
Caspase-3, Caspase-8, Caspase-9, Bcl-2 and Bax Protein Expressed in Tumor Tissues by Western Blot
A part of tumor tissues collected in RIPA buffer was used for protein analysis. Protein concentration was measured using bicinechonic acid assay. Equal concentrations of proteins (100 µg) were separated by 8% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride membranes. The membranes were blocked with 1% casein solution for 2 h at room temperature. Primary antibodies against caspase-3, cleaved-caspase-3, caspase-8, cleaved-caspase-8, caspase-9, cleaved-caspase-9, Bcl-2 and Bax were incubated for 1 h at 37°C with the following dilution factors: caspase-3 (1:1000), cleaved-caspase-3 (1:1000), caspase-8 (1:1000), cleaved-caspase-8 (1:1000), caspase-9 (1:1000), cleaved-caspase-9 (1:1000), Bcl-2 (1:1000) and Bax (1:1000). Membranes were rinsed 5 times with PBST buffer for 3 min each before incubation with the peroxidase-conjugated streptavidin-secondary for 1 h at 1:10000 dilution. Protein levels were visualized with chemiluminescence solution and X-ray films. β-tubulin was used as a loading control. Films were scanned and the average optical densities of the bands were analyzed with ONE-DScan system.

Statistical Analysis
Parametric data were expressed as means ± SD (±s). GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, United States) was used to analyze the data. Statistical significance was determined by using one-way analysis of variance [One-way ANOVA]. Differences with P < 0.05 were considered significant.

RESULTS
Analysis of CHB-II-F in Blood Serum
Ultra-high performance liquid chromatography -MS was used to analyze the serum of mice treated with CHB-II-F. Four components/metabolites (β-Sitosterol, Salvianolic acid B, isobavachalcone and bakuchiol) were identified by comparing the two serum ion profiles. The retention time at each phase was 9.62, 9.79, 11.27, and 43.95 min, respectively (Figures 2, 3).

Effects of CHB-II-F on Body Weight Change, Tumor Weights and Volume
After 14 days of treatment, body weight in all CHB-II-F groups was significantly higher than that of untreated group (P < 0.01) (Figure 4C). Compared with the untreated group, tumor volume of CHB-II-F groups were significantly smaller on the 7th day and there was a trend of the higher dose the smaller body weight (P < 0.01) (Figure 4A). On the 14th day, both tumor weight and volume in the CHB-II-F (H) group were further decreased significantly (P < 0.05) (Figures 4B,D). The post-chemotherapy tumor inhibitory ratios (IRs) were 38.51, 27.51, 51.34, 52.08, and 39.85% in CHB-II-F (L), CHB-II-F (M), CHB-II-F (H), 5-FU and YZXJC groups, respectively.

Effects of CHB-II-F on Pathology of Tumor Tissues
In the process of tumor removal, the tumor tissue was examined with the surrounding tissues. In the untreated group, the tumor was irregular in shape, large in volume and rough at the edges. After sectioning and staining with H&E, the nuclei were abnormally large, sizes of tumor cells varied, and the nuclei and cytoplasm were deeply stained. Tumor cells were arranged homogeneously and densely. In the 5-FU group, tumor cells were loosely arranged, cell number was decreased, and liquefactive necrosis and mitosis could be seen. Compared with both the saline and YZXJC groups, CHB-II-F treated groups showed scattered cell distribution, decreased tumor cell density, mitosis and heterogeneity within the tissue sections (Figure 5).

Effects of CHB-II-F on Ultramicro-Pathology and Apoptosis in Tumor Cells
The ultrastructure of tumor cells in each group was observed by transmission electron microscope. Compared with the untreated group, all other groups exhibited different degrees of cell shrinkage and fragmentation, cytoplasmic condensation, irregular morphologies of nuclear and plasma membranes and condensed and peripheralized chromatin. Red arrows marked the locations of apoptotic bodies and pyknotic nucleus (Figure 6).

Effects of CHB-II-F on Tumor Cell Cycle
The results of PI staining from flow cytometry revealed that the percentage of tumor cells in G0-G1 transition in the CHB-II-F (M) and CHB-II-F (H) groups was significantly higher, while the percentage in S phase was significantly decreased compared with the untreated group (P < 0.05; P < 0.01). However, the percentage of tumor cells in G2-M transition in all groups was not significantly different from that of the untreated group (Figure 7).

Effects of CHB-II-F on Tumor Cell Apoptotic Index
Annexin-V/PI staining was employed to detect early and late apoptotic cells. Figure 8 showed that the apoptotic index (%), defined as the percentage of apoptotic cells in all tumor cell population, were higher in all treated groups compared to the untreated group, with 5-FU and CHB-II-F (H) being statistically significant (P < 0.05).

Effects of CHB-II-F on Expression of Caspase-3, Caspase-8, Caspase-9, Bax and Bcl-2 in Tumor Tissue
Western blotting showed that the expression of cleaved caspase-3 was significantly increased in 5-FU group as well as all the CHB-II-F-treated groups. The expression of cleaved caspase-8 was significantly increased in 5-FU and all treated groups except CHB-II-F(L) group. In addition, cleaved caspase-9 was increased in both 5-FU and CHB-II-F(M) groups. Compared to
the untreated group, there was a slight decrease in the expression of apoptotic regulator, Bcl-2, in the CHB-II-F(L) and CHB-II-F(M) groups, but the expression of pro-apoptotic protein, Bax, was significantly higher in all three CHB-II-F groups. As a result, the ratio of Bax/Bcl-2 in all three CHB-II-F groups were higher (Figure 9).
DISCUSSION

Malignant tumor is the abnormal growth of cells in the human body, which has the ability to proliferate uncontrollably and metastasize. Millions of people are diagnosed with malignant tumors every year, and the incidence overall has been on the rise (Marusyk et al., 2012; Miller et al., 2016; Siegel et al., 2017; Chen et al., 2018). Malignant tumor in China alone accounts for about 21.8% of all cancer morbidity, among which, the incidence of hepatocellular carcinoma accounts for 50.5% and marks it as one of the major causes of cancer death in China and the third leading causes of cancer death in the world (Torre et al., 2015; Chen et al., 2017). Hepatocellular carcinoma is an aggressive disease with high malignancy, rate of recurrence and metastasis even after treatment, accompanied by short survival time and poor prognosis. At present, methods to control hepatocellular carcinoma include radiotherapy, chemotherapy, surgical resection, cryoablation, liver transplantation and interventional therapy, but patient outcomes have proven unsatisfactory (Ciarimboli, 2012; Xi et al., 2014; Wang et al., 2015). In China, the use of TCM as an adjuvant treatment for hepatocellular carcinoma has been shown to relief pain, reduce cytotoxicity of chemotherapy, improve symptoms of cancer, and control recurrence and metastasis (Song et al., 2016). Due to the relative low cost and ease of administration, TCM has gained recognition and used as an adjuvant therapy for chemotherapy (Chinese Society of Liver Cancer [CSLC], 2009). For instance, some Chinese medicine, such as the Yiqi Huayu Jiedu prescription, has...
FIGURE 5 | Effects of CHB-II-F on pathological changes of tumor tissue in the chemotherapy-treated H22 hepatocellular carcinoma mouse model. Sections were stained with hematoxylin and eosin (H&E) and viewed at a magnification of 400x. (A) Saline treated control (Negative control); (B) 5-FU treated control (20 mg/kg); (C) CHB-II-F (16.25 g/kg); (D) CHB-II-F (32.5 g/kg); (E) CHB-II-F (65 g/kg); (F) Yangzheng Xiaoji Capsule treated control (0.78 g/kg).

been used as regular treatment for patients with hepatocellular carcinoma after radiotherapy and chemotherapy, which has been demonstrated to inhibit tumor angiogenesis by downregulating HIF-1α, Twist1, Bcl-2, MMP-2, MMP-9 and upregulating E-cad (Zeng et al., 2015). Radix Sophorae Flavescentis has been shown to inhibit the growth of lung adenocarcinoma cells in vitro and slow the growth of Lewis lung cancer cells and ascitic carcinoma cells of tumor-bearing mouse in vivo (Lin et al., 2009). Hydroxycamptothecin embolization combined with Shentao Ruangan pills can effectively improve the therapeutic effect of large hepatoma and improve patient survival (Lin et al., 2005). The aim of our experiment was to study the adjuvant effect of CHB-II-F on hepatocellular carcinoma after chemotherapy, and to explore the components/metabolites and mechanism of CHB-II-F in promoting cancer cell apoptosis.

Despite the aggressive and chaotic liver cancer phenotype, it often progresses in an orderly manner. Often, a cell acquires a mutation in its tumor suppressor gene or in other regulator of cell proliferation, causing it to enter an altered and malicious path (Hanahan and Weinberg, 2011; Shafie et al., 2013). Following that, changes in cell morphology, surface protein expression and cell cycle regulation quickly follow and ultimately lead to the development of tumor population and associated complications (Rieger, 2004). The ultimate goal of cancer treatment is to kill cancerous cells without affecting normal cells (Ma et al., 2015). With the rapid increase in scientific knowledge and technological advances, cancer mortality has been greatly reduced, but not without consequences (Holohan et al., 2013; Simard et al., 2013). While radiotherapy and chemotherapy kill rapidly dividing cells such as cancer cells, they inevitably cause damage to other normal growing cells in the body. It is therefore necessary to identify ways to target apoptosis to only cancer cells and spare normal cells (Shafie et al., 2013). Many TCMs have inhibitory effects on cancer cells, which mechanisms involve in promoting tumor cell apoptosis. Therefore, applying Chinese herbs to treat cancer is a wise choice (Newman and Cragg, 2012; Wang et al., 2015; Cao et al., 2017).

All eukaryotic cells have a defined cell cycle in which physiological processes such as growth, replication, division, senescence and death resume (King and Cidlowski, 1995). Cell cycle is controlled by a sophisticated and precise
regulatory mechanism, and dysregulation leads to uncontrolled proliferation of cells and tumor formation (Wyllie et al., 1980). Whether a cell undergoes division or apoptosis is dictated by signals received during the cell cycle (Hartwell, 1992; Nurse, 1997). Usually, when a cell is blocked at a certain phase for prolonged period, apoptosis occurs. Many tumor chemotherapeutic agents treat tumor by inducing cell cycle-specific apoptosis (Collins et al., 1997). In this study, flow cytometry was used to analyze the effect of CHB-II-F on H22 hepatoma cells. We found that the percentage of tumor cells arrested in G0-G1 transition in the CHB-II-F (M) and CHB-II-F (H) groups were significantly higher. This shows that CHB-II-F may effectively influence cell proliferation and promote cell apoptosis. Although the IR of CHB-II-F (H) group was slightly inferior to the IR of 5-FU group, the body weight of mice in three CHB-II-F groups was increased, and higher than that in 5-FU group. The body weight loss of mice in 5-FU group was very obvious. These results indicated that after chemotherapy, combining with herbal medicine CHB-II-F could reduce 5-FU’s side-effects to a certain extent.

Cell apoptosis is very important for tumor control (King and Cidlowski, 1998). Apoptosis is the programmed death of cells intricately controlled by complex intracellular programs. There are two main pathways regulating apoptosis: the intrinsic stress-induced pathway and the death receptor-mediated pathway (Strasser et al., 2000). The former is induced by stress signals within the cell that promote the release of cytochrome C from the mitochondria, and the latter is activated by death receptor binding on the plasma membrane (Taylor et al., 2008). There are four major factors involved in the apoptotic pathway: Bcl-2 family of proteins, the caspases, heat shock proteins, and the p53 tumor suppressor gene. The Bcl-2 family are further divided into two groups: pro-apoptosis and anti-apoptosis. Bcl-2 itself is anti-apoptotic, and is mainly found in the mitochondria and cytoplasm. Bax, the pro-apoptotic counterpart, is mainly distributed in the cytoplasm and translocates to the
mitochondrial membrane and disrupts mitochondrial integrity after receiving apoptotic signal. It is found that when a stress signal occurs, Bcl-2 and Bax form heterodimers, which decrease the availability of Bcl-2, and thus promote apoptosis of cells (Lee et al., 2014; Min et al., 2014). The caspases belong to the aspartyl specific cysteine protease family and play important roles in the signal transduction of apoptosis (Nuñez et al., 1998; Boyce et al., 2004; Xi et al., 2016). Based on the signaling cascade, caspases can be divided into two categories: primers and effectors, among which caspase-8 and caspase-9 belong to the primer group, while caspase-3 belongs to the effector group (Riedl and Shi, 2004; Fulda, 2009; Tait and Green, 2010; Reubold and Eschenburg, 2012; Würstle et al., 2012). Based on signals from the surrounding environment, a cell activates the apoptotic pathway by first cleaving and activating the cytoplasmic caspase-8, which then activates caspase-3. Pathways downstream of caspase-3 function to suppress inhibitors of apoptosis and inhibit the activity of proteases associated with DNA repair and mRNA splicing, which ultimately lead to chromatin condensation, nuclear and DNA fragmentation, cytoplasmic membrane blebbing (Fulda and Debatin, 2006). Mitochondria are the major regulatory organelles of apoptosis induced by stress signal (Wu et al., 2014). The opening of permeability transition pores in the inner and outer mitochondrial membranes leads to the release of cytochrome C, apoptosis activating factor-1 and other caspase activators. Cytochrome C and apoptosis activating factor-1 activate caspase-9, which in turn activates caspase-3 and a variety of endonucleases to induce morphological changes of apoptosis.
FIGURE 9 | Effects of CHB-II-F on protein expression of caspase-3, caspase-8, caspase-9, Bax and Bcl-2 in tumor tissue of the chemotherapy-treated H22 hepatocellular carcinoma mouse model. (A) Cleaved-caspase 3 protein level; (B) Caspase 3 protein level; (C) Cleaved-caspase 8 protein level; (D) Caspase 8 protein level; (E) Cleaved-caspase 9 protein level; (F) Caspase 9 protein level; (G) Bcl-2 protein level; (H) Bax protein level. Data were presented as the mean ± SD from 6 mice. Statistical analysis: ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared with the saline group; ♦P < 0.05, ♦♦P < 0.01 compared with the YZXJC group. (The same loading control was used for uncleaved and cleaved versions of the same protein, and for Bcl-2 and Bax for ease of comparison).
Fulcher and Debatin, 2004; Gu et al., 2014). Activated caspase-
3 is the key to inactivation of other apoptotic proteins, which
cause alterations in cell structure, cell cycle and DNA repair
(Bratto and Salvesen, 2010). Uncontrolled cell proliferation
and apoptosis are reasons for the occurrence of tumor, thus
regaining control of these pathways are the fundamental methods
to manager tumor growth (Shao et al., 2015). In this study,
the expression of Bcl-2, Bax, caspase-3, caspase-8 and caspase-
9 in tumor tissues were detected by western blotting, and the
cell cycle makers and apoptotic index of tumor cells were
detected by flow cytometry. The results showed that protein
expression of Bcl-2 in mice treated with CHB-II-F had a
downward trend, while expression of Bax were increased. The
expressions of activated caspase-3, -8 and -9 in tumor tissues
were also upregulated, thus promoting apoptosis of tumor cells.
These results demonstrated that the appropriate concentration
of CHB-II-F can inhibit expression of anti-apoptotic factors
and block proliferation of tumor cells, while at the same time
increase the pro-apoptotic factors to induce tumor cell death.
Thus, the efficacy of chemotherapeutic drugs in the treatment of
hepatocellular carcinoma was enhanced.

Based on the UPLC results, four components/metabolites
from CHB-II-F were found in the serum of treated mice:
β-Sitosterol, Salvianolic acid, isobavachalcone and bakuchiol. It
is worth noting that two of the monomers have anti-tumor
effects. β-Sitosterol is one of the sterols components widely
found in various vegetable oils, nuts and plant seed. It has many
important physiological and pharmacological functions, such as
lowering blood lipids, anti-inflammatory and cytotoxic effects
(Zhang et al., 2011; Xiao et al., 2015; Yuan et al., 2015). It
has been suggested that β-Sitosterol can effectively inhibit
the growth of hepatoma carcinoma cells, decrease mitochondrial
membrane potential, induce apoptosis and the up-regulation
of Bcl-2, cleaved caspase (3, 8, 9) expressions (Zhang et al.,
2011). β-Sitosterol can also induce apoptosis of human leukemia
cell line U937 by activating caspase-3 protease and regulating
Bax/Bcl-2 ratio (Park et al., 2007). Salvianolic acid B is a
water-soluble compound found in the plant Salvia miltiorrhiza,
which is its most active ingredient (Durairajan et al., 2008; Cao
et al., 2012). Salvianolic acid B has been reported to have anti-
tumor properties against cancers of the lung, liver, breast and
prostate and squamous cell carcinoma of the head and neck.
The proposed mechanisms include inhibition of nuclear gene
transcription, inhibition of tumor angiogenesis and induction of
tumor cells apoptosis with low toxicity to normal cells (Zhao
et al., 2007; Hao et al., 2009; Zhao et al., 2010; Zhang and
Lu, 2010). Isobavachalcone is a flavonoid with anticancer, anti-
inflammatory, antibacterial and other biological activities (Kuete
and Sandjo, 2012; Wang et al., 2012). Apoptosis of HepG2 cells
can be induced by isobavachalcone, which was found to be
related to an upregulated expression of Bcl-2 family proteins.
Alternatively, it can also induce apoptosis of neuroblastoma
by the intrinsic mitochondrial pathway (Nishimura et al.,
2007; Wang et al., 2012). Bakuchiol is a monoterpeneoid
phenolic component with many pharmacological activities,
such as antibacterial, antineoplastic, and anti-inflammatory
actions (Jiang et al., 2010; Huang et al., 2014). Studies have
shown that bakuchiol can inhibit breast cancer cells through
inducing apoptosis and S phase arrest (Li et al., 2016). These
components/metabolites of CHB-II-F found in the serum have
known inhibitory effects on tumor, which provided the basis for
exploring CHB-II-F effect on apoptosis of tumor cells. CHB-
II-F may be down-regulating the expression of Bcl-2 and up-
regulating the expression of Bax, while activating both caspase-3
caspase-9, fixing tumor cells in G0-G1 transition, increasing
the rate of apoptosis of tumor cells and stimulating cells to initiate
the process of apoptosis. Morphological hallmarks of apoptosis
were observed in the CHB-II-F groups, thus further confirmed
the anti-tumor effect of the medicine.

In addition to its anti-tumor effects, CHB-II-F has been
applied in clinics for many years, which has demonstrated repeatedly to reduce the side effects of gastrointestinal tract and improve dietary intake. Therefore, future studies can focus on identifying the underlying mechanisms. In addition, clinical trials in human patients treated with CHB-II-F would provide further confirmation on the beneficial effects observed in the current study.

CONCLUSION

Four major components/metabolites of CHB-II-F have been
identified in serum of mice treated with CHB-II-F. CHB-
II-F treatment increased food intake, reduced pathological
changes in tumor tissues and inhibited proliferation of tumor
cells in the chemotheraphy-treated HCC mouse model. The
mechanistic action of CHB-II-F may be related to regulating
expression of apoptotic factors and promote apoptosis of tumor
cells.

AUTHOR CONTRIBUTIONS

SX and YanhW participated in the study design. BF and SX wrote
the manuscript. YG, YX, and JY critically revised the manuscript.
BF, XZ, YanW, YQ, JW, SH, and DL carried out the experiments.
SX and YanW participated in the study design. BF and SX wrote
the manuscript. YG, YX, and JY critically revised the manuscript.
BF, XZ, YanW, YQ, JW, SH, and DL carried out the experiments.
BF and SX also performed the statistical analysis.

FUNDING

This work was supported by the Natural Science Foundation
of Fujian Province of China (No. 2018J01136), the National
Natural Science Foundation of China (No. 81202659), the
Xiamen Science and Technology Program Plan Grant (China)
(No. 3502Z20153027), and the Xiamen Science and Technology
Key Program Plan Grant (China) (No. 3502Z20100006).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at:
https://www.frontiersin.org/articles/10.3389/fphar.2018.01539/full#supplementary-material
REFERENCES

Balisterri, W. F., Bezerra, J. A., Jansen, P., Karpen, S. J., Snydeker, B. L., and Suchy, F. I. (2005). Intrahepatic cholestasis: summary of an American Association for the Study of Liver Diseases single-topic conference. Hepatology 42, 222–235. doi: 10.1002/hep.20729

Boyce, M., DeGertev, A., and Yuan, J. (2004). Caspases: an ancient cellular sword of Damocles. Cell Death Differ. 11, 29–37. doi: 10.1038/sj.cdd.4401339

Bratton, S. B., and Salvesen, G. S. (2010). Regulation of the Apaf-1-caspase-9 apoptosome. J. Cell Sci. 123, 3209–3214. doi: 10.1242/jcs.073643

Cao, W., Guo, X. W., Zheng, H. Z., Li, D. P., Jia, G. B., and Wang, J. (2012). Current progress of research on pharmacologic actions of salvianolic acid B. Chin. J. Integr. Med. 18, 316–320. doi: 10.1007/s11655-012-1052-8

Cao, Z. X., Yang, Y. T., Yu, S., Li, Y. Z., Wang, W. W., Huang, J., et al. (2017). CGRP, TRPA1 and TRPM8 Endothelial Cells Mediate Cell Adhesion in Inflamed Arteries. Front. Pharmacol. 20, 20–27. doi: 10.1016/j.jep.2016.07.028

Chen, W. Q., Zheng, R. S., Zhang, S. W., Zeng, H. M., Zou, X. N., and He, J. (2017). Pogostone induces autophagy and apoptosis involving PI3K/Akt/mTOR axis in human colorectal carcinoma HCT116 cells. J. Ethnopharmacol. 202, 20–27. doi: 10.1007/s10626-017-4522-5

Durairajan, S. S., Yuan, Q., Xie, L., Chan, W. S., Kum, W. F., Koo, I., et al. (2008). Apoptotic and angiogenic activity of Damocles. World J. Gastroenterol. 14, 222–227. doi: 10.3748/wjg.14.222

Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646–674. doi: 10.1016/j.cell.2011.02.013

Hao, Y., Xie, T., Korotcov, A., Zhou, Y., Pang, X., Shan, L., et al. (2009). Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways. Int. J. Cancer 124, 2220–2229. doi: 10.1002/ijc.24160

Hartwell, L. (1992). Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71, 543–546. doi: 10.1016/0092-8674(92)90586-2

Hollohan, C., Van, S. S., Longley, D. B., and Johnston, P. G. (2013). Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714–726. doi: 10.1038/nrc3599

Huang, S. H., Huang, M. Y., Jia, X. S., and Hong, R. (2014). Chemistry and Biology of Bakuchiol. Chin. J. Organ. Chem. 34, 2412–2423. doi: 10.6023/cjoc2014080105

Jiang, F., Zhou, X. R., Wang, Q., and Zhang, B. X. (2010). Cytotoxic effect and mechanism of bakuchiol and bakuchiol combined with psoralen on HK-2 cell. Chin. J. Pharmacol. Toxicol. 24, 50–58. doi: 10.3867/j.issn.1000-3002.2010.01.009

King, K. L., and Cidlowski, J. A. (1995). Cell cycle and apoptosis: common pathways to life and death. J. Cell. Biochem. 58, 175–180. doi: 10.1002/jcb.24058006

Kudo, M., Matsui, O., Izumi, N., Iijima, H., Kadoya, M., and Imai, Y. (2014). Liver Cancer Study Group of Japan, Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update. Oncology 87(Suppl. 1), 7–21. doi: 10.1159/000368141

Lee, H., Lee, H., Chang, Y., and Lee, D. (2014). ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. Oncotarget 5, 5138–5152. doi: 10.18632/oncotarget.2094

Li, L., Chen, X., Liu, C. C., Lee, L. S., Man, C., and Cheng, S. H. (2016). Phytoestrogen bakuchiol exhibits in vitro and in vivo anti-breast cancer effects by inducing S phase arrest and apoptosis. Front. Pharmacol. 7:128. doi: 10.3389/fphar.2016.00128

Li, P. F., Liu, P., and Wang, Y. H. (2017). The experience on treating malignant tumor by Wang Yan-hui. Tradit. Chin. Med. J. 16, 18–21. doi: 10.14046/j.ckzyb2002.2017.06.007

Li, X. H., Li, X. K., Cai, S. H., Tang, F. X., Zhong, X. Y., and Ren, X. D. (2003). Synergistic effects of nimesulide and 5-fluorouracil on tumor growth and apoptosis in the implanted hepatoma in mice. World J. Gastroenterol. 9, 936–940. doi: 10.3748/wjg.v9.i13.936

Lin, L. Z., Zhou, D. H., Chen, Y., Liu, Q. H., and Chen, X. C. (2009). Experimental study of anti-tumor effect of compound radix sophorae flavescens injection on lung cancer cells and hepatic carcinoma cells. Tradit. Chin. Drug Res. Clin. Pharmacol. 20, 21–23. doi: 10.13738/jissn.1003-9783.2009.01.007

Lin, L. Z., Zhou, D. H., Liu, K., Wang, F. J., Lan, S. Q., and Ye, X. W. (2005). Analysis on the prognostic factors in patients with large hepatocarcinoma treated by shentao ruangan pill and hydroxycamptothecine. Chin. J. Tradit. Chin. Med. 25, 1–7. doi: 10.13288/j.issn.1000-3002.2010.01.009

Liu, B. X. Z., Zou, X., Zhou, J. Y., and Wang, R. P. (2012). Summary on the experience of WANG Y an-hui in the treatment of tumor by syndrome differentiation based on Xiang thinking. China J. Tradit. Chin. Med. Pharmac. 24, 728–731. doi: 10.3867/j.issn.1000-3002.2012.11.021

Liu, B. Y., and Xie, M. (2018). Synergistic and attenuated effects of traditional Chinese medicine combined with 5-FU in the treatment of digestive system tumors. China Pharm. 20, 1224–1228. doi: 10.3969/j.issn.1008-049X.2017.07.018

Liu, J. N. (2012). Clinical research on Shenling Bassizhu Powder for leukopenia after chemotherapy. J. Tradit. Chin. Med. 53, 1038–1041. doi: 10.13288/j.11-2166/tr.2012.12.005

Liu, P., Wang, Y. H., Xi, S. Y., Zhao, X. Y., Wang, C. M., Cheng, Y., et al. (2017). Analysis on the clinical experience of WANG Yan-hui in the treatment of tumor by syndrome differentiation based on Xiang thinking. China J. Tradit. Chin. Med. Pharm. 32, 3005–3008.

Ma, C., Zhu, L., Wang, J., He, H., Chang, X., Gao, J., et al. (2015). Anti-inflammatory effects of water extract of Taxarcum mongolicum hand.-Mazz on
lipopolysaccharide-induced inflammation in acute lung injury by suppressing P38/Ark/MI^Tg^OR signaling pathway. *J. Ethnopharmacol.* 168, 349–355. doi: 10.1016/j.ejep.2015.03.068

Müller, J., Kavelaars, A., Dougherty, P. M., and Heijnen, C. J. (2018). Beyond the looking glass for cancer? *CA Cancer J. Clin.* 68, 271–289. doi: 10.3322/caac.21349

Min, Z., Wang, L. Jin, J., Wang, X., Zhu, B., Chen, H., et al. (2014). Pyrroloquinoline quinone induces cancer cell apoptosis via mitochondrial-Dependent pathway and down-regulating cellular Bcl-2 protein expression. *J. Cancer* 5, 609–624. doi: 10.7150/jca.9002

Newman, D. J., and Cragg, G. M. (2012). Natural products as sources of new drugs over the 30 years from 1981 to 2010. *J. Nat. Prod.* 75, 311–335. doi: 10.1021/np200996s

Nishimura, R., Tabata, K., Arakawa, M., Ito, Y., Kimura, Y., Akhisa, T., et al. (2007). Isoavatchalcone, a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma. *Biolog. Pharm. Bull.* 30, 1878–1883. doi: 10.1248/bpb.30.1878

Nuñez, G., Benedict, M. A., Hu, Y., and Inohara, N. (1998). Caspases: the proteases of the apoptotic pathway. *Oncogene* 17, 3237–3245. doi: 10.1038/sj.onc.1202581

Nurse, P. (1997). Checkpoint pathways come of age. *Semin. Oncol. Nurs.* 14, 23545–23558. doi: 10.3390/ijms141223545

Pan, L. L., Wang, A. Y., Huang, Y. Q., Luo, Y., and Ling, M. (2014). Mangiferin induces apoptosis by regulating Bcl-2 and Bax expression in the CNE2 nasopharyngeal carcinoma cell line. *Asian Pac. J. Cancer Prev.* 15, 7065–7068. doi: 10.7314/APPCPC.2014.15.17.7065

Park, C., Moon, D. O., Rhu, C. H., Choi, B. T., Lee, W. H., Kim, G. Y., et al. (2007). Beta-sitosterol induces anti-proliferation and apoptosis in human leukemia U937 cells through activation of caspase-3 and induction of Bax/Bcl-2 ratio. *Biol. Pharm. Bull.* 30, 1317–1323. doi: 10.1248/bpb.30.1317

Reubold, T. F., and Eschenburg, S. (2012). A molecular view on signal transduction of the apoptotic pathway. *Oncogene* 17, 3237–3245. doi: 10.1038/sj.onc.1202581

Riedl, S. J., and Shi, Y. (2004). Molecular mechanisms of caspase regulation during apoptosis. *Nat. Rev. Mol. Cell Biol.* 5, 897–907. doi: 10.1038/nrm1496

Riegert, P. T. (2004). The biology of cancer genetics. *Semin. Oncol. Nurs.* 20, 145–154. doi: 10.1053/JSON.2004.001

Shi, X., Liu, N. H., Esa, N. M., Ithnin, H., Saad, N., and Pandurangan, A. K. (2013). Pro-apoptotic effect of rice bran inositol hexaphosphate (IP6) on HT-29 colorectal carcinoma receiving chemotherapy. *J. Ethnopharmacol.* 145, 23545–23558. doi: 10.3390/ijms141223545

Shao, S. L., Liu, R., Sui, W. J., Zhao, B., Zhang, W. W., Yang, X. T., et al. (2015). Allicin induced apoptosis in colon cancer cells HT-29. *Genom. Appl. Plann.* 34, 227–233. doi: 10.13417/gab.034.000227

Siegel, R. L., Miller, K. D., and Jemal, A. (2017). Cancer statistics, 2017. *CA Cancer J. Clin.* 67, 6–30. doi: 10.3322/caac.21358

Simon, S., Thewes, B., Humphris, G., Dixon, M., Hayden, C., Mireskandari, S., et al. (2013). Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. *J. Cancer Surviv.* 7, 300–322. doi: 10.1007/s11764-013-0272-z

Song, H. X., Qiao, F., and Shao, M. (2016). Research advances in traditional Chinese medicine treatment for primary liver cancer. *J. Clin. Hepat.* 32, 174–177. doi: 10.3969/j.issn.1001-5256.2016.01.038

Strasser, A., O’Connor, L., and Dixit, V. M. (2000). Apoptosis signaling. *Annu. Rev. Biochem.* 69, 217–245. doi: 10.1146/annurev.biochem.69.1.217

Tait, S. W., and Green, D. R. (2010). Mitochondria and cell death: outer membrane permeabilization and beyond. *Nat. Rev. Mol. Cell Biol.* 11, 621–632. doi: 10.1038/nrm2952

Taylor, R. C., Cullen, S. P., and Martin, S. J. (2008). Apoptosis: controlled demolition at the cellular level. *Nat. Rev. Mol. Cell Biol.* 9, 231–241. doi: 10.1038/nrm2312
Zhang, Z. Q., Xing, Y. J., Hu, G. Q., and Xie, S. Q. (2011). Antiproliferative effects mechanism of β-sitosterol in hepatoma HepG2 cells. *China J. Chin. Meter. Med.* 36, 2145–2148. doi: 10.4268/cjcm20111529

Zhao, N., Guo, Z. X., Zhao, X., and Zhao, L. B. (2007). Chemical composition and pharmacological effects of *Salvia miltiorrhiza*. *World phytomed.* 22, 155–160. doi: 10.3969/j.issn.1674-5515.2007.04.003

Zhao, Y., Hao, Y., Ji, H., Fang, Y., Guo, Y., Sha, W., et al. (2010). Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo. *Cancer Pre. Res.* 3, 787–796. doi: 10.1158/1940-6207.CAPR-09-0243

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.